Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with givosiran under the National Health Act 1953, section 85 for the chronic treatment of AHP.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing givosiran.
Treatment specifics
To be eligible for initial PBS-subsidised treatment with givosiran, treatment must be initiated under the supervision of a healthcare professional experienced in the management of porphyria.
To be eligible for continuing PBS-subsidised treatment with givosiran, patients must be treated by, or in consultation with a healthcare professional experienced in the management of porphyria.
Authority applications
Applying for initial treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for initial authority approval to prescribe PBS-subsidised givosiran for the chronic treatment of AHP can be made:
- using the Online PBS Authorities system
- in writing and using HPOS Form upload
- in writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed chronic treatment of Acute Hepatic Porphyria - givosiran - initial authority application form
- relevant attachments.
Applying for continuing treatment
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Applications for continuing authority approval to prescribe PBS-subsidised givosiran for the chronic treatment of AHP can be made in:
- real time using the Online PBS Authorities system
- writing and using HPOS Form upload
- writing and mailed to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed chronic treatment of Acute Hepatic Porphyria - givosiran - continuing authority application form
- relevant attachments.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.